Previous 10 | Next 10 |
IRIDEX Corporation (IRIX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations Fuad Ahmad – Interim Chief Financial Officer Conference Call Participants Tom Stephan – St...
IRIDEX press release (NASDAQ:IRIX): Q1 GAAP EPS of -$0.15 beats by $0.01. Revenue of $13.39M (+12.0% Y/Y) misses by $0.02M. Guidance for Full Year 2022: Total revenue for the full year is expected to be $57 million to $59 million vs. $58.50M consensus. For further details see: IRIDEX GA...
MOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2022. First Quarter 2022 Highlights Record first quarter revenue of $13.4 million, an increase of 12% from the prio...
MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first qua...
MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effect...
IRIDEX Corporation (IRIX) Q4 2021 Earnings Conference Call March 09, 2022, 05:00 PM ET Company Participants Hunter Cabi - IR Dave Bruce - CEO Fuad Ahmad - Interim CFO Conference Call Participants Tom Stephan - Stifel Scott Henry - ROTH Capital Presentation Operator Thank you for standing by, ...
IRIDEX press release (NASDAQ:IRIX): Q4 GAAP EPS of -$0.15. Revenue of $15.25M (+24.0% Y/Y). 2022 Guidance: Iridex projects Cyclo G6 probe sales of 67,000 to 70,000 representing 15% to 20% growth and Cyclo G6 systems installed base to expand by 225 to 250 in 2022. Total revenue for the full ye...
MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 1, 2022. Fourth Quarter Highlights Total revenue of $15.3 million, a new quarterly record, representing an...
MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 34 th A...
In addition to inflationary pressure, growing concerns about the potential aftermath of the Russia-Ukraine war and the Western and EU economic sanctions imposed on Russia have been fueling immense market volatility. So, we think investors seeking to 'bottom-fish' in the beaten-down market cou...
News, Short Squeeze, Breakout and More Instantly...
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company...